ME01312B - Heteroaril supstituirani pirol0[2,3-b]piridini i pirol0 [ 2,3-b]pirimidini kao inhibitori janus kinaze - Google Patents
Heteroaril supstituirani pirol0[2,3-b]piridini i pirol0 [ 2,3-b]pirimidini kao inhibitori janus kinazeInfo
- Publication number
- ME01312B ME01312B MEP-2011-199A MEP19911A ME01312B ME 01312 B ME01312 B ME 01312B ME P19911 A MEP19911 A ME P19911A ME 01312 B ME01312 B ME 01312B
- Authority
- ME
- Montenegro
- Prior art keywords
- pyrazol
- pyrrolo
- pyrimidin
- propanonitrile
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74990505P | 2005-12-13 | 2005-12-13 | |
| US81023106P | 2006-06-02 | 2006-06-02 | |
| US85062506P | 2006-10-10 | 2006-10-10 | |
| US85687206P | 2006-11-03 | 2006-11-03 | |
| US85940406P | 2006-11-16 | 2006-11-16 | |
| PCT/US2006/047369 WO2007070514A1 (en) | 2005-12-13 | 2006-12-12 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| EP06839328A EP1966202B1 (en) | 2005-12-13 | 2006-12-12 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME01312B true ME01312B (me) | 2013-12-20 |
Family
ID=37903501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2011-199A ME01312B (me) | 2005-12-13 | 2006-12-12 | Heteroaril supstituirani pirol0[2,3-b]piridini i pirol0 [ 2,3-b]pirimidini kao inhibitori janus kinaze |
Country Status (36)
Families Citing this family (433)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060106020A1 (en) * | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| JP2009508832A (ja) * | 2005-09-16 | 2009-03-05 | アストラゼネカ アクチボラグ | グルコキナーゼ活性化剤としてのヘテロ二環式化合物 |
| CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
| CA2628283C (en) * | 2005-11-01 | 2017-06-27 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| LT2455382T (lt) * | 2005-12-13 | 2017-02-10 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir prolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
| CN101389324A (zh) * | 2005-12-23 | 2009-03-18 | 史密丝克莱恩比彻姆公司 | Aurora激酶的氮杂吲哚抑制剂 |
| BRPI0709866B8 (pt) * | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
| RU2008143361A (ru) | 2006-04-05 | 2010-05-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Деазапурины в качестве ингибиторов янус-киназ |
| KR20090082507A (ko) | 2006-11-20 | 2009-07-30 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 통증 및 소양증 치료용 방법, 조성물 및 키트 |
| WO2008079965A1 (en) * | 2006-12-22 | 2008-07-03 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
| DK2740731T3 (en) * | 2007-06-13 | 2016-04-11 | Incyte Holdings Corp | CRYSTALLINE SALTS OF JANUSKINASEINHIBITOREN (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-CYCLOPENTYLPROPANNITRIL |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| US20100240657A1 (en) * | 2007-07-02 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Chemical compounds |
| WO2009032338A1 (en) * | 2007-09-09 | 2009-03-12 | University Of Florida Research Foundation | Apratoxin therapeutic agents: mechanism and methods of treatment |
| WO2009049028A1 (en) * | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| AU2008317406B2 (en) * | 2007-10-25 | 2013-07-18 | Merck Sharp & Dohme Corp. | Therapeutic compounds |
| EA020777B1 (ru) * | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
| WO2009098236A1 (en) * | 2008-02-06 | 2009-08-13 | Novartis Ag | Pyrrolo [2, 3-d] pyridines and use thereof as tyrosine kinase inhibitors |
| WO2009114552A1 (en) * | 2008-03-10 | 2009-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| HRP20161390T1 (hr) * | 2008-03-11 | 2016-12-02 | Incyte Holdings Corporation | Derivati azetidina i ciklobutana kao inhibitori jak |
| AU2009274454A1 (en) * | 2008-04-21 | 2010-01-28 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| CA2722326A1 (en) * | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| US8344144B2 (en) * | 2008-06-18 | 2013-01-01 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| PE20110063A1 (es) * | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
| BRPI0910021A2 (pt) * | 2008-06-20 | 2015-09-01 | Genentech Inc | "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinas em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase" |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| JOP20190230A1 (ar) * | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| US8765727B2 (en) * | 2009-01-23 | 2014-07-01 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| WO2010135621A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| MX2011012353A (es) * | 2009-05-22 | 2011-12-14 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus. |
| CN102459267B (zh) | 2009-06-08 | 2014-11-26 | 武田药品工业株式会社 | 用作jak抑制剂的二氢吡咯并萘啶酮化合物 |
| SG177384A1 (en) | 2009-06-29 | 2012-02-28 | Incyte Corp | Pyrimidinones as pi3k inhibitors |
| CA2767646C (en) | 2009-07-10 | 2019-01-29 | President And Fellows Of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EP2485589A4 (en) | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYL-BTK INHIBITORS |
| RU2538204C2 (ru) * | 2009-09-10 | 2015-01-10 | Ф.Хоффманн-Ля Рош Аг | Ингибиторы jak |
| EP3431084A1 (en) | 2009-10-02 | 2019-01-23 | Avexxin AS | Antiinflammatory 2-oxothiazoles |
| BR112012008267B1 (pt) * | 2009-10-09 | 2022-10-04 | Incyte Holdings Corporation | Derivados hidroxila, ceto e glucuronida de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1- il)-3-ciclopentilpropanonitrila |
| US8389728B2 (en) * | 2009-11-06 | 2013-03-05 | The Arizona Board Of Regents | Pollen tube stimulants from Arabidopsis pistils |
| US20110207754A1 (en) * | 2010-02-18 | 2011-08-25 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
| WO2011109217A2 (en) * | 2010-03-02 | 2011-09-09 | Immunodiagnostics, Inc. | Methods of treating or preventing rna polymerase dependent viral disorders by administration of jak2 kinase inhibitors |
| AU2015205858B2 (en) * | 2010-03-10 | 2017-04-13 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| US8765734B2 (en) * | 2010-03-10 | 2014-07-01 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| WO2011130146A1 (en) * | 2010-04-14 | 2011-10-20 | Array Biopharma Inc. | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AU2011255443B2 (en) | 2010-05-21 | 2014-07-03 | Incyte Holdings Corporation | Topical formulation for a JAK inhibitor |
| CN103119045B (zh) * | 2010-08-20 | 2016-02-17 | 和记黄埔医药（上海）有限公司 | 吡咯并嘧啶化合物及其用途 |
| AU2011305315A1 (en) * | 2010-09-24 | 2013-03-28 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| AU2011320565A1 (en) | 2010-10-28 | 2013-05-23 | Innocrin Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| EA036970B1 (ru) * | 2010-11-19 | 2021-01-21 | Инсайт Холдингс Корпорейшн | Применение {1-{1-[3-фтор-2-(трифтометил)изоникотиноил] пиперидин-4-ил}-3-[4-(7h-пирроло[2,3-d]пиримидин-4-ил)-1н-пиразол-1-ил]азетидин-3-ил}ацетонитрила для лечения заболеваний, связанных с активностью jak1 |
| SG190839A1 (en) * | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| EP2640725B1 (en) | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| WO2012082817A1 (en) * | 2010-12-16 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| AR084366A1 (es) | 2010-12-20 | 2013-05-08 | Incyte Corp | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k |
| AU2012214085B2 (en) | 2011-02-11 | 2015-07-09 | Nicoventures Trading Limited | Inhaler component |
| BR112013020798B1 (pt) | 2011-02-18 | 2022-03-15 | Incyte Corporation | Uso e composição contendo uma combinação de um inibidor mtor e de um inibidor de jak para tratamento de neoplasisas mieloproliferativas |
| JP5947998B2 (ja) * | 2011-02-24 | 2016-07-06 | セファロン、インク． | 置換芳香族硫黄化合物およびその利用方法 |
| US9115133B2 (en) | 2011-03-22 | 2015-08-25 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| CN103502249A (zh) * | 2011-05-17 | 2014-01-08 | 普林斯匹亚生物制药公司 | 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物 |
| PE20140604A1 (es) | 2011-06-14 | 2014-05-13 | Novartis Ag | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| WO2013008095A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
| JP2014521725A (ja) | 2011-08-10 | 2014-08-28 | ノバルティス・ファルマ・アクチェンゲゼルシャフト | ＪＡＫＰＩ３Ｋ／ｍＴＯＲ併用療法 |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| KR102249236B1 (ko) | 2011-09-02 | 2021-05-10 | 인사이트 홀딩스 코포레이션 | Ｐｉ３ｋ 억제제로서 헤테로시클릴아민 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| ES2640911T3 (es) * | 2011-09-22 | 2017-11-07 | Merck Sharp & Dohme Corp. | Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus |
| EP2766368A1 (en) * | 2011-10-12 | 2014-08-20 | Array Biopharma Inc. | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| MX2014006479A (es) * | 2011-11-30 | 2015-01-22 | Univ Emory | Inhibidores antivirales de la janus cinasa utiles en el tratamiento o prevencion de infecciones retrovirales y otras infecciones virales. |
| US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| US8993756B2 (en) * | 2011-12-06 | 2015-03-31 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| EP3882249B1 (en) | 2012-06-15 | 2025-05-14 | Sun Pharmaceutical Industries, Inc. | Deuterated derivatives of ruxolitinib |
| SG10201805807PA (en) | 2012-06-26 | 2018-08-30 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
| EP2877162A1 (en) * | 2012-07-27 | 2015-06-03 | ratiopharm GmbH | Oral dosage forms for modified release comprising ruxolitinib |
| WO2014019908A2 (en) | 2012-08-02 | 2014-02-06 | Nerviano Medical Sciences S.R.L. | Substituted pyrroles active as kinases inhibitors |
| WO2014045305A1 (en) | 2012-09-21 | 2014-03-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| BR112015007513A2 (pt) * | 2012-10-26 | 2017-07-04 | Hoffmann La Roche | inibidores de tirosina quinase de bruton |
| MX2015005428A (es) | 2012-11-01 | 2015-07-21 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak). |
| NZ748448A (en) | 2012-11-15 | 2019-12-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| US9310374B2 (en) * | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| NZ748966A (en) * | 2012-12-06 | 2020-05-29 | Baruch S Blumberg Inst | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| CA2899137C (en) | 2013-01-29 | 2021-07-13 | Avexxin As | Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds |
| EP2954330A4 (en) | 2013-02-08 | 2016-08-31 | Inst Myeloma & Bone Cancer Res | IMPROVED DIAGNOSTIC, PROGNOSTIC AND MONITORING PROCEDURES FOR MULTIPLE MYELOMA, CHRONIC LYMPHATIC LEUKEMIA AND NON-HODGKIN B CELL LYMPHOMA |
| WO2014126037A1 (ja) * | 2013-02-12 | 2014-08-21 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子及び照明装置 |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| SMT202300352T1 (it) | 2013-05-17 | 2024-01-10 | Incyte Holdings Corp | Derivati bipirazolici come inibitori di jak |
| EP3721873A1 (en) * | 2013-08-07 | 2020-10-14 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
| SG11201601119XA (en) | 2013-08-20 | 2016-03-30 | Incyte Corp | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| US9611263B2 (en) | 2013-10-08 | 2017-04-04 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP6276852B2 (ja) * | 2013-10-15 | 2018-02-07 | ジン，ボハン | 新規化合物、使用およびそれらの調製のための方法 |
| US20160375024A1 (en) | 2013-11-27 | 2016-12-29 | Novartis Ag | Combination therapy comprising an inhibitor of jak, cdk, and pim |
| RS56728B1 (sr) | 2013-12-05 | 2018-03-30 | Pfizer | Pirolo[2,3-d]pirimidinil, pirolo[2,3-b]pirazinil i pirolo[2,3-d]piridinil akrilamidi |
| JP6367545B2 (ja) * | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| KR102261733B1 (ko) * | 2013-12-18 | 2021-06-04 | 콘서트 파마슈티컬즈, 인크. | 룩소리티닙의 중수소화된 유도체 |
| CN110229159B (zh) * | 2013-12-18 | 2021-08-24 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| RS57723B1 (sr) | 2014-02-28 | 2018-12-31 | Incyte Corp | Jak1 inhibitori za lečenje mijelodisplastičnog sindroma |
| CA2940666C (en) | 2014-02-28 | 2022-08-23 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| HRP20192346T1 (hr) | 2014-03-14 | 2020-03-20 | Novartis Ag | Molekule anti-lag-3 antitijela i njihove uporabe |
| SI3129021T1 (sl) | 2014-04-08 | 2021-07-30 | Incyte Corporation | Zdravljenje malignosti B-celic s kombinacijo zaviralcev JAK in PI3K |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| RU2564891C1 (ru) * | 2014-05-27 | 2015-10-10 | Александр Александрович Кролевец | Способ получения нанокапсул цитокининов |
| WO2015184087A2 (en) * | 2014-05-28 | 2015-12-03 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| CN105218548A (zh) * | 2014-06-09 | 2016-01-06 | 上海海和药物研究开发有限公司 | 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途 |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| NZ629796A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| CN106715427A (zh) * | 2014-07-14 | 2017-05-24 | 西格诺药品有限公司 | 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法 |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| WO2016024232A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
| EP3179992B1 (en) | 2014-08-11 | 2022-05-11 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor |
| HUE056329T2 (hu) | 2014-08-11 | 2022-02-28 | Acerta Pharma Bv | BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi |
| CN117164657A (zh) | 2014-08-12 | 2023-12-05 | 莫纳什大学 | 定向淋巴的前药 |
| EP3183252B1 (en) * | 2014-08-21 | 2021-05-12 | ratiopharm GmbH | Oxalate salt of ruxolitinib |
| WO2016040880A1 (en) | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| CN105524067A (zh) * | 2014-09-28 | 2016-04-27 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
| JP2017535528A (ja) | 2014-10-03 | 2017-11-30 | ノバルティス アーゲー | 組み合わせ治療 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
| WO2016063294A2 (en) * | 2014-10-20 | 2016-04-28 | Msn Laboratories Private Limited | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof |
| CA2965754C (en) | 2014-10-29 | 2024-01-02 | Bicycle Therapeutics Limited | Bicyclic peptide ligands specific for mt1-mmp |
| GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| CZ2014773A3 (cs) | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
| CN105777754B (zh) * | 2014-12-16 | 2019-07-26 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
| TWI788655B (zh) | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| MX388606B (es) | 2015-02-27 | 2025-03-19 | Incyte Holdings Corp | Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparacion. |
| MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| KR101859170B1 (ko) * | 2015-04-17 | 2018-05-17 | 광주과학기술원 | 트리아졸 화합물 및 이의 용도 |
| EP3290418B1 (en) * | 2015-04-29 | 2019-05-15 | Wuxi Fortune Pharmaceutical Co., Ltd | Janus kinase (jak) inhibitors |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CZ2015496A3 (cs) | 2015-07-14 | 2017-01-25 | Zentiva, K.S. | Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava |
| WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| US20180222982A1 (en) | 2015-07-29 | 2018-08-09 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| HUE055469T2 (hu) | 2015-07-29 | 2021-11-29 | Novartis Ag | A LAG-3 elleni antitest molekulákat tartalmazó kombinált terápiák |
| CA2994545A1 (en) | 2015-08-03 | 2017-02-09 | President And Fellows Of Harvard College | Charged ion channel blockers and methods for use |
| US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
| WO2017035366A1 (en) * | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| US10023571B2 (en) | 2015-09-02 | 2018-07-17 | Nimbus Lakshimi, Inc. | TYK2 inhibitors and uses thereof |
| US11738087B2 (en) | 2015-09-08 | 2023-08-29 | Monash University | Lymph directing prodrugs |
| WO2017044720A1 (en) | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| CA3001703C (en) | 2015-10-23 | 2024-05-21 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
| AU2016348391A1 (en) | 2015-11-03 | 2018-05-17 | Janssen Biotech, Inc. | Antibodies specifically binding TIM-3 and their uses |
| MA43169B1 (fr) | 2015-11-06 | 2022-05-31 | Incyte Corp | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma |
| AU2016354009B2 (en) | 2015-11-09 | 2021-05-20 | R.P. Scherer Technologies, Llc | Anti-CD22 antibody-maytansine conjugates and methods of use thereof |
| RU2601410C1 (ru) * | 2015-11-13 | 2016-11-10 | ЗАО "Р-Фарм" | {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ |
| EP3389664A4 (en) | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF |
| CN108368115B (zh) * | 2015-12-15 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的盐 |
| RU2018125603A (ru) | 2015-12-17 | 2020-01-21 | Новартис Аг | Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения |
| JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Ｐｄ−１に対する抗体分子およびその使用 |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| EP3398952B1 (en) * | 2015-12-31 | 2021-07-14 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Synthesis process of ruxolitinib |
| DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
| CZ201629A3 (cs) | 2016-01-22 | 2017-08-02 | Zentiva, K.S. | Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy |
| US10822339B2 (en) | 2016-01-26 | 2020-11-03 | Hangzhou Huadong Medicine Group Biopharmaceutical Co. Ltd | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof |
| CN105541891B (zh) * | 2016-02-04 | 2017-11-28 | 东南大学 | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 |
| EP4234552A3 (en) | 2016-03-09 | 2023-10-18 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| DK3426243T3 (da) | 2016-03-09 | 2021-07-19 | Raze Therapeutics Inc | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| KR102558066B1 (ko) | 2016-03-28 | 2023-07-25 | 인사이트 코포레이션 | Tam 억제제로서 피롤로트리아진 화합물 |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| HUE068643T2 (hu) | 2016-05-04 | 2025-01-28 | Sun Pharmaceutical Ind Inc | Hajhullási rendellenességek kezelése deuterált JAK-inhibitorokkal |
| PL3464266T3 (pl) | 2016-06-01 | 2022-01-24 | Bayer Animal Health Gmbh | Podstawione indazole użyteczne do leczenia i zapobiegania chorobom alergicznym i/lub zapalnym u zwierząt |
| CN107513067A (zh) * | 2016-06-16 | 2017-12-26 | 北京赛林泰医药技术有限公司 | 含有取代环戊基的吡咯并嘧啶化合物 |
| CN107759600A (zh) * | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
| CN107513069A (zh) * | 2016-06-16 | 2017-12-26 | 正大天晴药业集团股份有限公司 | 手性吡咯并嘧啶化合物的制备方法 |
| CN109562106B (zh) | 2016-06-21 | 2023-03-21 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
| EP3950691A1 (en) | 2016-06-30 | 2022-02-09 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| EP3492469B1 (en) * | 2016-07-26 | 2021-12-01 | Suzhou Longbiotech Pharmaceuticals Co., Ltd. | Compound as selective jak inhibitor, and salt and therapeutic use thereof |
| RU2019108280A (ru) | 2016-08-24 | 2020-09-25 | Аркьюл, Инк. | Аминопирролопиримидиноновые соединения и способы их применения |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| IT201600092051A1 (it) * | 2016-09-13 | 2018-03-13 | Alessandro Antonelli | Composto medicale per il trattamento di tumori della tiroide |
| CA3039202A1 (en) | 2016-10-14 | 2018-04-19 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| JP7082120B2 (ja) | 2016-10-21 | 2022-06-07 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| US10414727B2 (en) | 2016-11-08 | 2019-09-17 | Navitor Pharmaceuticals, Inc. | Phenyl amino piperidine mTORC inhibitors and uses thereof |
| JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
| US11091451B2 (en) | 2016-12-05 | 2021-08-17 | Raze Therapeutics, Inc. | SHMT inhibitors and uses thereof |
| RU2644155C1 (ru) * | 2016-12-12 | 2018-02-08 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | 2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ |
| EP3559018A1 (en) | 2016-12-23 | 2019-10-30 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| EA039352B1 (ru) * | 2017-01-19 | 2022-01-17 | Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. | Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение |
| US10336752B2 (en) | 2017-03-08 | 2019-07-02 | Nimbus Lakshmi, Inc. | TYK2 inhibitors, uses, and methods for production thereof |
| EP3375778A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
| EP3375784A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridone derivatives |
| US11339144B2 (en) | 2017-04-10 | 2022-05-24 | Navitor Pharmaceuticals, Inc. | Heteroaryl Rheb inhibitors and uses thereof |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| TWI776886B (zh) | 2017-04-26 | 2022-09-11 | 美商奈維特製藥公司 | Sestrin-gator2交互作用之調節劑及其用途 |
| US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| NZ759764A (en) | 2017-05-23 | 2022-07-01 | Theravance Biopharma R&D Ip Llc | Glucuronide prodrugs of janus kinase inhibitors |
| US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| US10899798B2 (en) | 2017-06-26 | 2021-01-26 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| CN107298680A (zh) * | 2017-07-12 | 2017-10-27 | 海门华祥医药科技有限公司 | 一种4‑氯‑7‑氮杂吲哚的生产工艺 |
| IL317854A (en) | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| US11261214B2 (en) | 2017-08-04 | 2022-03-01 | Bicycletx Limited | Bicyclic peptide ligand specific for CD137 |
| US20200283482A1 (en) | 2017-08-14 | 2020-09-10 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
| US20200291096A1 (en) | 2017-08-14 | 2020-09-17 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| WO2019046491A1 (en) | 2017-08-29 | 2019-03-07 | Ariya Therapeutics, Inc. | LIPIDIC PRODRUGS DIRECTING TO THE LYMPHATIC SYSTEM |
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| AU2018338314B2 (en) | 2017-09-22 | 2024-12-12 | Kymera Therapeutics, Inc | Protein degraders and uses thereof |
| MD3687996T2 (ro) | 2017-09-27 | 2022-04-30 | Incyte Corp | Săruri de derivați de pirolotriazină utile ca inhibitori TAM |
| CN109651424B (zh) * | 2017-10-11 | 2021-01-22 | 新发药业有限公司 | 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法 |
| WO2019090158A1 (en) | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
| WO2019090143A1 (en) * | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrimidine-5-carboxylate analogs and methods of making the same |
| KR102034538B1 (ko) | 2017-11-28 | 2019-10-21 | 주식회사한국파마 | Jak 저해제 화합물, 및 이의 제조방법 |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| WO2019126378A1 (en) | 2017-12-19 | 2019-06-27 | Ariya Therapeutics, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN111918651B (zh) | 2018-01-29 | 2024-01-30 | 默克专利股份有限公司 | Gcn2抑制剂及其用途 |
| EP3746071A4 (en) | 2018-01-29 | 2021-09-01 | Merck Patent GmbH | GCN2 INHIBITORS AND THEIR USES |
| SI3746429T1 (sl) | 2018-01-30 | 2023-01-31 | Incyte Corporation | Postopki za pripravo (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona) |
| KR20240158365A (ko) | 2018-02-16 | 2024-11-04 | 인사이트 코포레이션 | 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제 |
| BR112020014576A2 (pt) | 2018-02-23 | 2020-12-08 | Bicycletx Limited | Ligantes peptídicos bicíclicos multiméricos |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| AU2019229258B2 (en) | 2018-02-27 | 2023-09-14 | Artax Biopharma Inc. | Chromene derivatives as inhibitors of TCR-Nck interaction |
| EP3762424A1 (en) | 2018-03-08 | 2021-01-13 | Novartis AG | Use of an anti-p-selectin antibody |
| CN110357887B (zh) * | 2018-03-26 | 2022-09-16 | 武汉誉祥医药科技有限公司 | 取代的7H-吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 |
| PT3773593T (pt) | 2018-03-30 | 2024-06-25 | Incyte Corp | Tratamento da hidradenite supurativa com inibidores de jak |
| MA52655A (fr) | 2018-03-30 | 2021-02-17 | Incyte Corp | Biomarqueurs pour maladie cutanée inflammatoire |
| MX2020010815A (es) | 2018-04-13 | 2020-12-11 | Incyte Corp | Biomarcadores para enfermedad de injerto contra hospedero. |
| JP7304892B2 (ja) | 2018-04-24 | 2023-07-07 | メルク パテント ゲーエムベーハー | 抗増殖性化合物およびその使用 |
| AR114828A1 (es) | 2018-04-24 | 2020-10-21 | Vertex Pharma | Compuestos de pteridinona y sus usos |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| SG11202011680YA (en) | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| EP3805219A4 (en) * | 2018-06-06 | 2022-03-23 | Gengle Therapeutics, Inc. | PYRAZOLOPYRIMIDI DERIVATIVE, ITS USE AND PHARMACEUTICAL COMPOSITION |
| PT3813946T (pt) | 2018-06-15 | 2024-07-10 | Janssen Pharmaceutica Nv | Análogos da rapamicina e suas utilizações |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| PT3813800T (pt) | 2018-06-29 | 2025-06-06 | Incyte Corp | Formulações de um inibidor de axl/mer |
| JP6830460B2 (ja) * | 2018-07-05 | 2021-02-17 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| EP3817748A4 (en) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | TRICYCLIC CRBN LIGANDS AND USES THEREOF |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| CN117281803A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| JP7591500B2 (ja) | 2018-08-10 | 2024-11-28 | アクラリス セラピューティクス，インコーポレイテッド | ピロロピリミジンｉｔｋ阻害剤 |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| US12030875B2 (en) | 2018-09-07 | 2024-07-09 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| AU2019360941B2 (en) | 2018-10-15 | 2025-02-27 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| CN113164414A (zh) | 2018-10-24 | 2021-07-23 | 纳维托制药有限公司 | 多晶型化合物和其用途 |
| EP3873433A1 (en) | 2018-10-31 | 2021-09-08 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| WO2020112937A1 (en) | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2020113233A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN109394768B (zh) * | 2018-12-10 | 2019-08-23 | 牡丹江医学院 | 一种治疗湿疹的药物及其制备方法 |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| WO2020131627A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| KR20210107069A (ko) | 2018-12-21 | 2021-08-31 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 컨쥬게이트와 키나아제 저해제의 조합 |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| CN113348021B (zh) | 2019-01-23 | 2025-07-11 | 武田药品工业株式会社 | Tyk2抑制剂和其用途 |
| WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| CN111620873B (zh) * | 2019-02-28 | 2021-12-28 | 沈阳药科大学 | 一类含哌啶的吡咯并[2,3-d]嘧啶衍生物及其制备和用途 |
| SG11202109563WA (en) | 2019-03-05 | 2021-09-29 | Incyte Corp | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| MX2021010870A (es) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Bloqueadores de canales ionicos cargados y metodos de uso. |
| US10934263B2 (en) | 2019-03-11 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10828287B2 (en) | 2019-03-11 | 2020-11-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| KR102887727B1 (ko) | 2019-03-11 | 2025-11-18 | 녹시온 테라퓨틱스 인코포레이티드 | 에스테르 치환된 이온 채널 차단제 및 사용 방법 |
| WO2020191041A2 (en) | 2019-03-19 | 2020-09-24 | Incyte Corporation | Biomarkers for vitiligo |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP3946462A1 (en) | 2019-04-02 | 2022-02-09 | BicycleTX Limited | Bicycle toxin conjugates and uses thereof |
| JP2022527114A (ja) | 2019-04-05 | 2022-05-30 | カイメラ セラピューティクス， インコーポレイテッド | 分解剤およびそれらの使用 |
| US11548895B2 (en) | 2019-04-24 | 2023-01-10 | Elanco Us Inc. | Process for making crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile |
| WO2020223728A1 (en) | 2019-05-02 | 2020-11-05 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as jak inhibitors |
| KR102286372B1 (ko) | 2019-05-27 | 2021-08-05 | 주식회사한국파마 | Jak 저해제 화합물, 및 이를 포함하는 의약 조성물 |
| CN110028509B (zh) * | 2019-05-27 | 2020-10-09 | 上海勋和医药科技有限公司 | 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途 |
| AU2020284742A1 (en) * | 2019-05-28 | 2022-02-03 | Mankind Pharma Ltd. | Novel compounds for inhibition of Janus Kinase 1 |
| CN114502540A (zh) | 2019-05-31 | 2022-05-13 | 医肯纳肿瘤学公司 | Tead抑制剂和其用途 |
| US12521438B2 (en) | 2019-06-10 | 2026-01-13 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| US11602536B2 (en) * | 2019-06-10 | 2023-03-14 | Incyte Corporation | Topical treatment of vitiligo by a JAK inhibitor |
| CN114269372A (zh) | 2019-06-27 | 2022-04-01 | 克里斯珀医疗股份公司 | 嵌合抗原受体t细胞和nk细胞抑制剂用于治疗癌症的用途 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN110305140B (zh) | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| WO2021022178A1 (en) * | 2019-07-31 | 2021-02-04 | Aclaris Therapeutics, Inc. | Substituted sulfonamide pyrrolopyridines as jak inhibitors |
| US20220251097A1 (en) * | 2019-08-01 | 2022-08-11 | St. Jude Childrens's Research Hospital | Molecules and methods related to treatment of uncontrolled cellular proliferation |
| US11845724B2 (en) | 2019-09-11 | 2023-12-19 | Vincere Biosciences, Inc. | USP30 inhibitors and uses thereof |
| PH12022550605A1 (en) | 2019-09-13 | 2023-09-25 | Nimbus Saturn Inc | Hpk1 antagonists and uses thereof |
| CN114423786A (zh) | 2019-09-16 | 2022-04-29 | 诺华股份有限公司 | 高亲和力的、配体阻断性、人源化的抗T细胞免疫球蛋白结构域和粘蛋白结构域3（TIM-3）IgG4抗体用于治疗骨髓纤维化的用途 |
| TW202123941A (zh) | 2019-09-16 | 2021-07-01 | 瑞士商諾華公司 | Ｍｄｍ２抑制劑用於治療骨髓纖維化之用途 |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| CN110538183B (zh) * | 2019-10-09 | 2021-05-04 | 吉林大学 | 一种预防和治疗小儿湿疹的组合物及其制备方法 |
| WO2021072098A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US12203942B2 (en) | 2019-10-10 | 2025-01-21 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| JP7518900B2 (ja) | 2019-10-16 | 2024-07-18 | インサイト・コーポレイション | 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用 |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| WO2021087432A1 (en) | 2019-11-01 | 2021-05-06 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mtorc1 modulator |
| AU2020380118A1 (en) | 2019-11-06 | 2022-05-19 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| EP4054586A4 (en) | 2019-11-06 | 2023-11-22 | Nocion Therapeutics, Inc. | CHARGED ION CHANNEL BLOCKERS AND METHOD OF USE |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| IL293085A (en) | 2019-11-22 | 2022-07-01 | Incyte Corp | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
| EP4069223A4 (en) | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | RAPAMYCIN ANALOGS AND THEIR USES |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| PH12022551522A1 (en) | 2019-12-23 | 2024-01-29 | Kymera Therapeutics Inc | Smarca degraders and uses thereof |
| AU2020417293A1 (en) | 2020-01-03 | 2022-09-01 | Berg Llc | Polycyclic amides as UBE2K modulators for treating cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AU2021217172A1 (en) | 2020-02-05 | 2022-09-22 | Monash University | Lipid prodrugs of neurosteroids |
| CN111728975A (zh) * | 2020-02-25 | 2020-10-02 | 广东省检迅检测科技有限公司 | 用于减少运动损伤和促进运动损伤修复的组合物 |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| EP4114401A1 (en) | 2020-03-06 | 2023-01-11 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| US11332446B2 (en) | 2020-03-11 | 2022-05-17 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CA3171258A1 (en) | 2020-03-19 | 2021-09-23 | Nan JI | Mdm2 degraders and uses thereof |
| WO2021206766A1 (en) | 2020-04-09 | 2021-10-14 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| US11324750B2 (en) | 2020-04-09 | 2022-05-10 | Children's Hospital Medical Center | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection |
| EP3892280A3 (en) | 2020-04-09 | 2022-01-12 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| HRP20241560T1 (hr) | 2020-06-02 | 2025-01-17 | Incyte Corporation | Postupci za proizvodnju inhibitora jak1 |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| PH12022553276A1 (en) | 2020-06-03 | 2024-02-19 | Incyte Corp | Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| AU2021282596A1 (en) | 2020-06-05 | 2023-01-19 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| WO2021260657A1 (en) | 2020-06-26 | 2021-12-30 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| US11751108B2 (en) * | 2020-08-05 | 2023-09-05 | Qualcomm Incorporated | Execution of reduced signaling handover |
| CA3194469A1 (en) * | 2020-08-12 | 2022-02-17 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| JP2023538906A (ja) | 2020-08-17 | 2023-09-12 | バイシクルティーエクス・リミテッド | ネクチン－４に特異的な二環コンジュゲート及びその使用 |
| IL300557A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a JAK1 inhibitor |
| IL300555A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a JAK inhibitor |
| CN116137815B (zh) * | 2020-09-16 | 2025-08-19 | 埃克斯索生物制药有限公司 | 嘧啶并嘧啶酮化合物及包含其的药物组合物 |
| WO2022061351A1 (en) | 2020-09-16 | 2022-03-24 | Incyte Corporation | Topical treatment of vitiligo |
| JP2023544728A (ja) | 2020-10-02 | 2023-10-25 | インサイト・コーポレイション | 扁平苔癬の治療のための局所ルキソリチニブ |
| EP4225316A1 (en) | 2020-10-08 | 2023-08-16 | Novartis AG | Use of an erk inhibitor for the treatment of myelofibrosis |
| EP4225317A1 (en) | 2020-10-08 | 2023-08-16 | Novartis AG | Use of an erk inhibitor for the treatment of myelofibrosis |
| EP4232425A4 (en) | 2020-10-23 | 2024-07-24 | Nimbus Clotho, Inc. | Ctps1 inhibitors and uses thereof |
| CN114437079B (zh) * | 2020-10-30 | 2024-11-01 | 杭州邦顺制药有限公司 | 吡咯嘧啶五元氮杂环化合物的晶型 |
| KR102551758B1 (ko) | 2020-11-30 | 2023-07-05 | 주식회사한국파마 | 신규한 jak 특이 저해제 화합물, 및 이의 제조방법 |
| KR20230131189A (ko) | 2020-12-02 | 2023-09-12 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| SI4255442T1 (sl) | 2020-12-04 | 2025-06-30 | Incyte Corporation | Zaviralec jak z analogom vitamina d za zdravljenje kožnih bolezni |
| JP2023552452A (ja) | 2020-12-08 | 2023-12-15 | インサイト・コーポレイション | 白斑治療用のｊａｋ１経路阻害薬 |
| CN117242080A (zh) | 2020-12-18 | 2023-12-15 | 勃林格殷格翰动物保健美国公司 | 含硼吡唑化合物、包括其的组合物、其方法和用途 |
| US12150995B2 (en) | 2020-12-30 | 2024-11-26 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| TW202237083A (zh) | 2021-01-11 | 2022-10-01 | 美商英塞特公司 | 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法 |
| WO2022165530A1 (en) * | 2021-02-01 | 2022-08-04 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| WO2022167457A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| WO2022166796A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
| EP4291235A4 (en) | 2021-02-12 | 2025-01-08 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| IL304905A (en) | 2021-02-15 | 2023-10-01 | Kymera Therapeutics Inc | IRAK4 joints and their uses |
| CA3207049A1 (en) | 2021-02-15 | 2022-08-18 | Jared Gollob | Irak4 degraders and uses thereof |
| EP4297750A1 (en) | 2021-02-25 | 2024-01-03 | Impact Biomedicines, Inc. | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis |
| WO2022187856A1 (en) | 2021-03-05 | 2022-09-09 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| US12071442B2 (en) | 2021-03-29 | 2024-08-27 | Nimbus Saturn, Inc. | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists |
| CA3214952A1 (en) | 2021-04-09 | 2022-10-13 | Silvana Marcel LEIT DE MORADEI | Cbl-b modulators and uses thereof |
| CA3215081A1 (en) | 2021-04-16 | 2022-10-20 | Alfredo C. Castro | Mek inhibitors and uses thereof |
| MA64472B1 (fr) | 2021-05-03 | 2025-11-28 | Incyte Corporation | Inhibiteurs de la voie jak1 pour le traitement du prurigo nodulaire |
| IL308314A (en) | 2021-05-07 | 2024-01-01 | Kymera Therapeutics Inc | CDK2 compounds and their uses |
| CA3226714A1 (en) | 2021-07-12 | 2023-01-19 | Incyte Corporation | Process and intermediates for preparing baricitinib |
| EP4384175A1 (en) | 2021-08-11 | 2024-06-19 | Sun Pharmaceutical Industries, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| EP4392422A1 (en) | 2021-08-25 | 2024-07-03 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| KR102718345B1 (ko) * | 2021-09-16 | 2024-10-17 | 광주과학기술원 | 신규한 트리아졸릴피롤로피리미딘 유도체 및 이의 용도 |
| US20240376102A1 (en) * | 2021-09-18 | 2024-11-14 | Natco Pharma Limited | An improved process for the preparation of ruxolitinib phosphate |
| IL312330A (en) | 2021-10-25 | 2024-06-01 | Kymera Therapeutics Inc | Tyk2 degraders and uses thereof |
| TW202334165A (zh) | 2021-10-29 | 2023-09-01 | 美商凱麥拉醫療公司 | Irak4降解劑及其製備 |
| US12290565B2 (en) | 2021-11-17 | 2025-05-06 | Altrubio Inc. | Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers |
| WO2023102559A1 (en) | 2021-12-03 | 2023-06-08 | Incyte Corporation | Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN114044777B (zh) * | 2022-01-10 | 2022-04-19 | 南京佰麦生物技术有限公司 | 一种磷酸芦可替尼的制备方法 |
| EP4472967A2 (en) | 2022-01-31 | 2024-12-11 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN114456181A (zh) * | 2022-02-21 | 2022-05-10 | 浙江乐普药业股份有限公司 | 一种芦可替尼的制备方法 |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
| WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| EP4540252A1 (en) * | 2022-06-14 | 2025-04-23 | Incyte Corporation | Solid forms of a jak inhibitor and process of preparing the same |
| CN117384163A (zh) * | 2022-07-05 | 2024-01-12 | 盛世泰科生物医药技术(苏州)股份有限公司 | 一种含偕二氟基的化合物及其制备方法和用途 |
| CN120051456A (zh) | 2022-08-02 | 2025-05-27 | 里米诺生物科学有限公司 | 取代的吡啶酮gpr84拮抗剂及其用途 |
| KR20250057800A (ko) | 2022-08-02 | 2025-04-29 | 리미널 바이오사이언시스 리미티드 | 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도 |
| JP2025527247A (ja) | 2022-08-02 | 2025-08-20 | リミナル・バイオサイエンシーズ・リミテッド | アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用 |
| WO2024028193A1 (en) | 2022-08-03 | 2024-02-08 | Medichem, S.A. | Stable oral pharmaceutical formulation containing ruxolitinib hemifumarate |
| IL314750A (en) * | 2022-08-22 | 2024-10-01 | Granules India Ltd | IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB |
| WO2024099396A1 (zh) * | 2022-11-11 | 2024-05-16 | 浙江奥翔药业股份有限公司 | 芦可替尼晶体及其药物组合物 |
| WO2024112894A1 (en) | 2022-11-22 | 2024-05-30 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| WO2024184926A1 (en) * | 2023-03-08 | 2024-09-12 | Aarti Pharmalabs Limited | Process for preparation of chiral ruxolitinib and salts thereof |
| WO2024187416A1 (en) * | 2023-03-15 | 2024-09-19 | Zhejiang Qizheng Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising ruxolitinib |
| WO2024187415A1 (en) * | 2023-03-15 | 2024-09-19 | Zhejiang Qizheng Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising ruxolitinib |
| US20240398810A1 (en) | 2023-05-21 | 2024-12-05 | Incyte Corporation | Topical ruxolitinib foam |
| EP4620470A3 (en) | 2023-06-23 | 2025-10-08 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4491175A1 (en) | 2023-07-10 | 2025-01-15 | Genepharm S.A. | A solid oral composition of ruxolitinib |
| CN121194977A (zh) | 2023-09-04 | 2025-12-23 | 印度颗粒有限公司 | 用于制备芦可替尼及其新晶型的改良方法 |
| IT202300018879A1 (it) | 2023-09-14 | 2025-03-14 | Chemelectiva S R L | Processo enzimatico per la preparazione di (r)-3-(4-bromo-1h-pirazol-1-il)-3- ciclopentilpropanenitrile, quale intermedio nella sintesi di ruxolitinib |
| WO2025062372A1 (en) | 2023-09-21 | 2025-03-27 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| US12364699B2 (en) | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
| WO2025117642A1 (en) | 2023-12-01 | 2025-06-05 | Incyte Corporation | Ruxolitinib for treating hidradenitis suppurativa (hs) |
| EP4621803A1 (en) | 2024-03-22 | 2025-09-24 | Assistance Publique - Hôpitaux de Paris | Method for identifying patients in need for ici-induced myotoxicity treatment |
| WO2025207818A1 (en) * | 2024-03-27 | 2025-10-02 | Gilead Sciences, Inc. | Small molecule modulators of stat6 |
| WO2025226637A1 (en) | 2024-04-22 | 2025-10-30 | Incyte Corporation | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor |
Family Cites Families (311)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2985589A (en) * | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
| US3632836A (en) | 1968-10-25 | 1972-01-04 | Dow Chemical Co | Solid curable polyepoxides modified with hydrolyzed liquid polyepoxides |
| US3832460A (en) | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
| DE3220113A1 (de) * | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
| US4402832A (en) * | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
| US4404335A (en) | 1982-08-16 | 1983-09-13 | The Dow Chemical Company | Hydrolyzing epoxy resins in absence of solvent and in presence of oxalic acid and a phosphonium compound |
| US4548990A (en) * | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US4498991A (en) * | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
| NL8403224A (nl) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
| CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
| US4921947A (en) | 1986-03-31 | 1990-05-01 | Eli Lilly And Company | Process for preparing macrolide derivatives |
| JPH0710876Y2 (ja) | 1989-08-31 | 1995-03-15 | 石垣機工株式会社 | スクリュープレスにおける脱水筒の洗浄装置 |
| JP2541702B2 (ja) | 1989-10-11 | 1996-10-09 | 帝人株式会社 | 二環性ピリミジン誘導体、その製造方法およびそれを有効成分とする医薬製剤 |
| US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
| IT1258781B (it) * | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| FR2695126B1 (fr) | 1992-08-27 | 1994-11-10 | Sanofi Elf | Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant. |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| JPH0710876A (ja) * | 1993-06-24 | 1995-01-13 | Teijin Ltd | ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン |
| USH1439H (en) | 1993-10-18 | 1995-05-02 | The Dow Chemical Company | Method to increase the level of α-glycol in liquid epoxy resin |
| EP0727217A3 (en) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient |
| IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU6478396A (en) | 1995-07-05 | 1997-02-05 | E.I. Du Pont De Nemours And Company | Fungicidal pyrimidinones |
| CZ1598A3 (cs) | 1995-07-06 | 1998-04-15 | Novartis Ag | Pyrrolopyrimidiny a způsoby jejich přípravy |
| US5630943A (en) * | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| WO1997036587A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | A method of treating cancer |
| AU2802297A (en) | 1996-04-18 | 1997-11-07 | Merck & Co., Inc. | A method of treating cancer |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| AU3215197A (en) | 1996-05-30 | 1998-01-05 | Merck & Co., Inc. | A method of treating cancer |
| US6624138B1 (en) | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
| EP0973396A4 (en) | 1997-04-07 | 2001-02-07 | Merck & Co Inc | METHOD FOR TREATING CANCER |
| US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
| US6063284A (en) | 1997-05-15 | 2000-05-16 | Em Industries, Inc. | Single column closed-loop recycling with periodic intra-profile injection |
| JP2001513502A (ja) * | 1997-08-11 | 2001-09-04 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | ５，６−ヘテロアリールジピリド［２，３−ｂ：３’，２’−ｆ］アゼピン類及びＨＩＶ感染の予防及び治療におけるそれらの使用 |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
| SE9800729L (sv) | 1998-03-06 | 1999-09-07 | Scotia Lipidteknik Ab | Ny topikal formulering I |
| US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| EP1090009A2 (en) | 1998-06-04 | 2001-04-11 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| PT1087970E (pt) | 1998-06-19 | 2004-06-30 | Pfizer Prod Inc | Compostos pirrolo¬2,3-d|pirimidina |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| JP4516690B2 (ja) | 1998-08-11 | 2010-08-04 | ノバルティス アーゲー | 血管形成阻害活性を有するイソキノリン誘導体 |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| ES2190241T3 (es) | 1998-09-10 | 2003-07-16 | Nycomed Danmark As | Compuestos farmaceuticos de liberacion rapida de substancias medicamentosas. |
| US6375839B1 (en) * | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
| US6413419B1 (en) * | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
| FR2785196B1 (fr) * | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| JP2002538121A (ja) | 1999-03-03 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | プレニルタンパク質トランスフェラーゼの阻害剤 |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| AU3565999A (en) | 1999-04-16 | 2000-11-02 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| WO2001027104A1 (en) | 1999-10-13 | 2001-04-19 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| US7235258B1 (en) | 1999-10-19 | 2007-06-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating CNS-mediated disorders |
| EP1235830B1 (en) | 1999-12-10 | 2004-01-02 | Pfizer Products Inc. | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS |
| WO2001047922A2 (en) * | 1999-12-24 | 2001-07-05 | Aventis Pharma Limited | Azaindoles |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| DE60100866T2 (de) * | 2000-04-07 | 2004-07-29 | Laboratoire Medidom S.A. | Cyklosporin, Hyaluronsäure und Polysorbate enthaltenes Augenarzneimittel |
| WO2001081345A1 (en) | 2000-04-20 | 2001-11-01 | Mitsubishi Pharma Corporation | Aromatic amide compounds |
| EP3029041B1 (en) * | 2000-04-25 | 2020-03-04 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| US7498304B2 (en) * | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| IL153115A0 (en) | 2000-06-16 | 2003-06-24 | Curis Inc | Angiogenesis-modulating compositions and uses |
| US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| AU2001274598A1 (en) | 2000-06-23 | 2002-01-02 | Mitsubishi Pharma Corporation | Antitumor effect potentiators |
| KR100516419B1 (ko) * | 2000-06-26 | 2005-09-23 | 화이자 프로덕츠 인크. | 면역억제제로서 피롤로[2,3-ｄ]피리미딘 화합물 |
| AU2002215608B2 (en) | 2000-06-28 | 2004-12-09 | Smithkline Beecham P.L.C. | Wet milling process |
| WO2002016370A1 (en) | 2000-08-22 | 2002-02-28 | Hokuriku Seiyaku Co., Ltd. | 1h-imidazopyridine derivatives |
| JP4377583B2 (ja) | 2000-12-05 | 2009-12-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃ−ｊｕｎｎ末端キナーゼ（ｊｎｋ）および他のタンパク質キナーゼのインヒビター |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| JP2004520347A (ja) | 2001-01-15 | 2004-07-08 | グラクソ グループ リミテッド | Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体 |
| CA2436487A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd. | Methods of inhibiting kinases |
| AU2002308748A1 (en) | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| CA2455181C (en) | 2001-08-01 | 2010-04-06 | Merck & Co., Inc. | Benzimidazo[4,5-f]isoquinolinone derivatives |
| CN100391958C (zh) | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | 化合物 |
| US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
| NZ532136A (en) | 2001-10-30 | 2006-08-31 | Novartis Ag | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
| JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
| WO2003048111A1 (fr) * | 2001-11-30 | 2003-06-12 | Teijin Limited | Procede pour produire un compose d'acide 5-(3-cyanophenyl)-3-formylbenzoique |
| GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| MXPA04010225A (es) | 2002-04-15 | 2005-07-05 | Adams Lab Inc | Liberacion sostenida de la combinacion de guaifenesina con farmacos. |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US7304061B2 (en) * | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| CA2483084A1 (en) | 2002-05-02 | 2003-11-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| KR20100120243A (ko) * | 2002-05-07 | 2010-11-12 | 피시비다 유에스 인코포레이티드 | 약물 전달 장치를 형성하는 공정 |
| CA2486183C (en) | 2002-05-23 | 2012-01-10 | Cytopia Pty Ltd. | Protein kinase inhibitors |
| AR037647A1 (es) | 2002-05-29 | 2004-12-01 | Novartis Ag | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina |
| US7385018B2 (en) * | 2002-06-26 | 2008-06-10 | Idemitsu Kosan Co., Ltd. | Hydrogenated copolymer, process for producing the same, and hot-melt adhesive composition containing the same |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| US20060004010A1 (en) | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| WO2004026406A1 (en) | 2002-09-20 | 2004-04-01 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| US20040204404A1 (en) * | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| EP1562938B1 (en) | 2002-11-04 | 2007-08-29 | Vertex Pharmaceuticals Incorporated | Heteroaryl-pyrimidine derivatives as jak inhibitors |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| US20040099204A1 (en) | 2002-11-25 | 2004-05-27 | Nestor John J. | Sheet, page, line, position marker |
| WO2004047843A1 (en) | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| TWI335819B (en) * | 2002-12-24 | 2011-01-11 | Alcon Inc | Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| US7135493B2 (en) | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
| US7444183B2 (en) | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
| EP1611125A1 (en) | 2003-02-07 | 2006-01-04 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| WO2004092154A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| FR2857454B1 (fr) | 2003-07-08 | 2006-08-11 | Aventis Pasteur | Dosage des acides techoiques des bacteries gram+ |
| US20050043346A1 (en) * | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
| EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| KR101154175B1 (ko) * | 2003-10-24 | 2012-06-14 | 산텐 세이야꾸 가부시키가이샤 | 각결막 장해 치료제 |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| JP2007512316A (ja) | 2003-11-25 | 2007-05-17 | ファイザー・プロダクツ・インク | アテローム性動脈硬化症の治療方法 |
| AU2004305317A1 (en) | 2003-12-17 | 2005-07-07 | Pfizer Products Inc. | Pyrrolo [2,3-D] pyrimidine compounds for treating transplant rejection |
| WO2005066147A1 (en) * | 2003-12-19 | 2005-07-21 | Schering Corporation | Thiadiazoles as cxc- and cc- chemokine receptor ligands |
| HRP20141228T1 (en) | 2003-12-19 | 2015-03-13 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
| EP2228369A1 (en) | 2003-12-23 | 2010-09-15 | Astex Therapeutics Ltd. | Pyrazole derivatives as protein kinase modulators |
| US20050153989A1 (en) * | 2004-01-13 | 2005-07-14 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| CA2559285A1 (en) | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| PL1730146T3 (pl) | 2004-03-30 | 2011-10-31 | Vertex Pharma | Azaindole użyteczne jako inhibitor JAK i innych kinaz białkowych |
| JP5213229B2 (ja) | 2004-04-23 | 2013-06-19 | エグゼリクシス， インコーポレイテッド | キナーゼ調節因子および使用方法 |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| US7558717B2 (en) | 2004-04-28 | 2009-07-07 | Vertex Pharmaceuticals Incorporated | Crystal structure of human JAK3 kinase domain complex and binding pockets thereof |
| EP2363149A1 (en) | 2004-05-03 | 2011-09-07 | Novartis AG | Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor |
| US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| ES2396135T3 (es) | 2004-06-10 | 2013-02-19 | Irm Llc | Compuestos y composiciones como inhibidores de proteínas cinasas |
| US8039674B2 (en) | 2004-06-23 | 2011-10-18 | Ono Pharmaceutical Co., Ltd. | Compound having S1P receptor binding potency and use thereof |
| EP1765819B1 (en) | 2004-06-30 | 2014-03-12 | Vertex Pharmaceuticals Inc. | Azaindoles useful as inhibitors of protein kinases |
| US7138423B2 (en) | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
| FR2873691B1 (fr) | 2004-07-29 | 2006-10-06 | Sanofi Synthelabo | Derives d'amino-piperidine, leur preparation et leur application en therapeutique |
| WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| WO2006022459A1 (en) | 2004-08-23 | 2006-03-02 | Mogam Biotechnology Institute | Primer and probe for detection of sars coronavirus, kit comprising the primer and/or the probe, and detection method thereof |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| BRPI0518152A (pt) * | 2004-10-13 | 2008-11-04 | Hoffmann La Roche | pirazolbenzodiazepinas dissubstituìdas úteis como inibidores para cdk2 e angiogênese e para o tratamento de cánceres de mama, cólon, pulmão e próstata |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| DE602005023763D1 (de) | 2004-11-04 | 2010-11-04 | Vertex Pharma | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine |
| WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| US7517870B2 (en) * | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
| US20060128803A1 (en) * | 2004-12-14 | 2006-06-15 | Alcon, Inc. | Method of treating dry eye disorders using 13(S)-HODE and its analogs |
| TW200635899A (en) | 2004-12-22 | 2006-10-16 | Astrazeneca Ab | Chemical compounds |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| WO2006077499A1 (en) | 2005-01-20 | 2006-07-27 | Pfizer Limited | Chemical compounds |
| CA2596830A1 (en) | 2005-02-03 | 2006-09-14 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrimidines useful as inhibitors of protein kinase |
| US7683171B2 (en) | 2005-02-04 | 2010-03-23 | Bristol-Myers Squibb Company | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| WO2006101783A2 (en) | 2005-03-15 | 2006-09-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| MX2007012393A (es) | 2005-04-05 | 2008-02-22 | Pharmacopeia Inc | Derivados de purina e imidazopiridina para la inmunosupresion. |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| CA2609126A1 (en) * | 2005-05-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
| SG151327A1 (en) | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
| WO2007044894A2 (en) | 2005-10-11 | 2007-04-19 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
| PL1937664T3 (pl) | 2005-10-14 | 2011-11-30 | Sumitomo Chemical Co | Związki hydrazydowe i ich zastosowanie jako pestycydy |
| CA2626375A1 (en) | 2005-10-28 | 2007-05-03 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
| CA2628283C (en) * | 2005-11-01 | 2017-06-27 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| WO2007062459A1 (en) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| US20130137681A1 (en) | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| LT2455382T (lt) * | 2005-12-13 | 2017-02-10 | Incyte Holdings Corporation | Heteroarilu pakeisti pirolo[2,3-b]piridinai ir prolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai |
| EP1968568A4 (en) | 2005-12-22 | 2011-04-13 | Glaxosmithkline Llc | HEMMER OF NUTS ACTIVITY |
| CN101389324A (zh) * | 2005-12-23 | 2009-03-18 | 史密丝克莱恩比彻姆公司 | Aurora激酶的氮杂吲哚抑制剂 |
| JP4643455B2 (ja) | 2006-01-12 | 2011-03-02 | 株式会社ユニバーサルエンターテインメント | 遊技システム |
| EP1973911B1 (en) | 2006-01-17 | 2016-01-13 | Vertex Pharmaceuticals Incorporated | Azaindoles useful for the treatment of (inter alia) proliferative, cardiac, neurodegenerative, autoimmune or inflammatory disorders |
| US20070208053A1 (en) * | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
| EP1981887A2 (en) * | 2006-02-01 | 2008-10-22 | SmithKline Beecham Corporation | Pyrrolo[2,3,b]pyridine derivatives useful as raf kinase inhibitors |
| US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| KR20080099334A (ko) | 2006-02-24 | 2008-11-12 | 테바 파마슈티컬 인더스트리즈 리미티드 | 메토프로롤 숙시네이트 서방정 및 이의 제조 방법 |
| MX2008011414A (es) * | 2006-03-10 | 2008-09-22 | Ono Pharmaceutical Co | Derivado heterociclico nitrogenado y agente farmaceutico que comprende el derivado como ingrediente activo. |
| BRPI0709866B8 (pt) * | 2006-04-03 | 2021-05-25 | Astellas Pharma Inc | compostos héteros e composição farmacêutica compreendendo ditos compostos |
| RU2008143361A (ru) | 2006-04-05 | 2010-05-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Деазапурины в качестве ингибиторов янус-киназ |
| CA2647448A1 (en) | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| WO2007135461A2 (en) | 2006-05-18 | 2007-11-29 | Bayer Healthcare Ag | Pharmaceutical compositions comprising implitapide and methods of using same |
| US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | Novartis Ag | 吡咯并嘧啶化合物及其用途 |
| NZ573174A (en) | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| BRPI0713187A2 (pt) * | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8492378B2 (en) * | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| JP5252404B2 (ja) * | 2006-08-16 | 2013-07-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピラジン化合物、その使用及び調製方法 |
| US20100029609A1 (en) | 2006-09-08 | 2010-02-04 | Frederic Berst | Biaryl sulfonamide derivatives |
| WO2008035376A2 (en) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof |
| WO2008043031A1 (en) | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc. | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| WO2008043019A1 (en) * | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc | 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression |
| US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| KR101546493B1 (ko) | 2006-11-06 | 2015-08-21 | 톨레로 파마수티컬스, 인크. | 이미다조[1,2-ｂ]피리다진 및 피라졸로[1,5-ａ]피리미딘 유도체 및 단백질 키나제 억제제로서의 이의 용도 |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| PL2497470T3 (pl) | 2006-11-22 | 2016-04-29 | Incyte Holdings Corp | Imidazotriazyny i imidazopirymidyny jako inhibitory kinazy |
| WO2008067119A2 (en) | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Novel compounds |
| NZ577111A (en) * | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
| WO2008079292A1 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
| EP2125781A2 (en) | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
| WO2008079965A1 (en) | 2006-12-22 | 2008-07-03 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
| US8389014B2 (en) | 2006-12-22 | 2013-03-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| WO2008082840A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| CA2679659C (en) | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| MY157724A (en) | 2007-04-03 | 2016-07-15 | Array Biopharma Inc | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| US8188178B2 (en) | 2007-05-07 | 2012-05-29 | 3M Innovative Properties Company | Cold shrinkable article including an epichlorohydrin composition |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| EP2155689B1 (en) | 2007-05-31 | 2015-07-08 | Boehringer Ingelheim International GmbH | Ccr2 receptor antagonists and uses thereof |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| CL2008001709A1 (es) * | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| DK2740731T3 (en) | 2007-06-13 | 2016-04-11 | Incyte Holdings Corp | CRYSTALLINE SALTS OF JANUSKINASEINHIBITOREN (R) -3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-CYCLOPENTYLPROPANNITRIL |
| CA2691914C (en) | 2007-07-11 | 2012-06-26 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
| KR20100038119A (ko) * | 2007-08-01 | 2010-04-12 | 화이자 인코포레이티드 | 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도 |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| CA2743756A1 (en) | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
| EA020777B1 (ru) | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
| GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| ES2598503T3 (es) * | 2008-01-18 | 2017-01-27 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Nuevos citostáticos nucleósidos 7-deazapurina |
| CA2714181C (en) | 2008-02-04 | 2013-12-24 | Mercury Therapeutics, Inc. | Ampk modulators |
| PE20091577A1 (es) | 2008-03-03 | 2009-11-05 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
| HRP20161390T1 (hr) | 2008-03-11 | 2016-12-02 | Incyte Holdings Corporation | Derivati azetidina i ciklobutana kao inhibitori jak |
| MX2010010317A (es) | 2008-03-21 | 2010-10-04 | Novartis Ag | Compuestos heterociclicos novedosos y usos de los mismos. |
| US8344144B2 (en) | 2008-06-18 | 2013-01-01 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| MX379265B (es) | 2008-06-26 | 2025-03-11 | Anterios Inc | Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel. |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| FR2933409B1 (fr) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
| TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物 |
| WO2010022081A1 (en) | 2008-08-19 | 2010-02-25 | Array Biopharma Inc. | Triazolopyridine compounds as pim kinase inhibitors |
| SI2384326T1 (sl) | 2008-08-20 | 2014-06-30 | Zoetis Llc | Pirolo(2,3-d)pirimidinske spojine |
| CA2735779A1 (en) | 2008-09-02 | 2010-03-11 | Matthew Burger | Bicyclic kinase inhibitors |
| PL2344474T3 (pl) | 2008-09-02 | 2016-03-31 | Novartis Ag | Pochodne pikolinamidu jako inhibitory kinaz |
| CN102197032B (zh) | 2008-09-02 | 2014-07-23 | 诺华股份有限公司 | 杂环pim-激酶抑制剂 |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| CA2739466A1 (en) | 2008-10-17 | 2010-04-22 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| MX2011012353A (es) | 2009-05-22 | 2011-12-14 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus. |
| WO2010135621A1 (en) | 2009-05-22 | 2010-11-25 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| WO2011003418A1 (en) | 2009-07-08 | 2011-01-13 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
| WO2011025685A1 (en) | 2009-08-24 | 2011-03-03 | Merck Sharp & Dohme Corp. | Jak inhibition blocks rna interference associated toxicities |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| WO2011029802A1 (en) | 2009-09-08 | 2011-03-17 | F. Hoffmann-La Roche Ag | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| BR112012008267B1 (pt) | 2009-10-09 | 2022-10-04 | Incyte Holdings Corporation | Derivados hidroxila, ceto e glucuronida de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1- il)-3-ciclopentilpropanonitrila |
| US9242987B2 (en) | 2009-10-20 | 2016-01-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors |
| US8671402B2 (en) | 2009-11-09 | 2014-03-11 | Bank Of America Corporation | Network-enhanced control of software updates received via removable computer-readable medium |
| EP2332917B1 (en) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
| US9468676B2 (en) | 2009-11-24 | 2016-10-18 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US20130129675A1 (en) | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
| CA2782720A1 (en) | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| AR079984A1 (es) | 2010-01-12 | 2012-03-07 | Hoffmann La Roche | Compuestos heterociclicos triciclicos, composiciones y su uso en el tratamiento de enfermedades mediadas por la inhibicion de jak1 |
| MX2012009074A (es) | 2010-02-05 | 2012-08-23 | Pfizer | Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa. |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| US20110207754A1 (en) * | 2010-02-18 | 2011-08-25 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
| US8765734B2 (en) | 2010-03-10 | 2014-07-01 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors |
| WO2011130146A1 (en) | 2010-04-14 | 2011-10-20 | Array Biopharma Inc. | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| AU2011255443B2 (en) | 2010-05-21 | 2014-07-03 | Incyte Holdings Corporation | Topical formulation for a JAK inhibitor |
| WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| US9351943B2 (en) | 2010-07-01 | 2016-05-31 | Matthew T. McLeay | Anti-fibroblastic fluorochemical emulsion therapies |
| WO2012045010A1 (en) | 2010-09-30 | 2012-04-05 | Portola Pharmaceuticals, Inc. | Combinations of 4-(3-(2h-1,2,3-triazo-2-yl) phenylamino)-2-((1r,2s)-2-aminocyclohexylamino) pyrimidine-5-carboxamide and fludarabine |
| SG190839A1 (en) * | 2010-11-19 | 2013-07-31 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| EP2640725B1 (en) * | 2010-11-19 | 2015-01-07 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| SG190950A1 (en) | 2010-12-03 | 2013-07-31 | Ym Biosciences Australia Pty | Treatment of jak2-mediated conditions |
| BR112013020798B1 (pt) * | 2011-02-18 | 2022-03-15 | Incyte Corporation | Uso e composição contendo uma combinação de um inibidor mtor e de um inibidor de jak para tratamento de neoplasisas mieloproliferativas |
| CN102247368B (zh) | 2011-05-19 | 2013-05-29 | 安徽永生堂药业有限责任公司 | 一种复方阿伐斯汀缓释片及其制备方法 |
| CN102218042A (zh) | 2011-05-26 | 2011-10-19 | 青岛黄海制药有限责任公司 | 富马酸喹硫平组合物的缓释片剂及其制备方法 |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| JP2014521725A (ja) | 2011-08-10 | 2014-08-28 | ノバルティス・ファルマ・アクチェンゲゼルシャフト | ＪＡＫＰＩ３Ｋ／ｍＴＯＲ併用療法 |
| TW201313721A (zh) * | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| EP3882249B1 (en) | 2012-06-15 | 2025-05-14 | Sun Pharmaceutical Industries, Inc. | Deuterated derivatives of ruxolitinib |
| EP2877162A1 (en) | 2012-07-27 | 2015-06-03 | ratiopharm GmbH | Oral dosage forms for modified release comprising ruxolitinib |
| CN102772384A (zh) | 2012-08-07 | 2012-11-14 | 四川百利药业有限责任公司 | 一种盐酸米诺环素缓释片及其制备方法 |
| JP2015526520A (ja) | 2012-08-31 | 2015-09-10 | プリンシピア バイオファーマ インコーポレイテッド | Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体 |
| MX2015005428A (es) | 2012-11-01 | 2015-07-21 | Incyte Corp | Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak). |
| NZ748448A (en) | 2012-11-15 | 2019-12-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| SMT202300352T1 (it) | 2013-05-17 | 2024-01-10 | Incyte Holdings Corp | Derivati bipirazolici come inibitori di jak |
| EP3721873A1 (en) | 2013-08-07 | 2020-10-14 | Incyte Corporation | Sustained release dosage forms for a jak1 inhibitor |
| SG11201601119XA (en) | 2013-08-20 | 2016-03-30 | Incyte Corp | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| RS57723B1 (sr) | 2014-02-28 | 2018-12-31 | Incyte Corp | Jak1 inhibitori za lečenje mijelodisplastičnog sindroma |
| SI3129021T1 (sl) | 2014-04-08 | 2021-07-30 | Incyte Corporation | Zdravljenje malignosti B-celic s kombinacijo zaviralcev JAK in PI3K |
| CN106687462A (zh) | 2014-04-30 | 2017-05-17 | 因赛特公司 | Jak1抑制剂的制备方法以及其新形式 |
| WO2015184087A2 (en) | 2014-05-28 | 2015-12-03 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| US10766900B2 (en) | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| WO2020163653A1 (en) | 2019-02-06 | 2020-08-13 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
-
2006
- 2006-12-12 LT LTEP11152730.5T patent/LT2455382T/lt unknown
- 2006-12-12 ES ES18191992T patent/ES2867505T3/es active Active
- 2006-12-12 PT PT111527305T patent/PT2455382T/pt unknown
- 2006-12-12 PT PT111527081T patent/PT2348023E/pt unknown
- 2006-12-12 EA EA201691294A patent/EA036785B1/ru active Protection Beyond IP Right Term
- 2006-12-12 NZ NZ778831A patent/NZ778831A/en unknown
- 2006-12-12 CA CA2632466A patent/CA2632466C/en active Active
- 2006-12-12 SI SI200631956T patent/SI2348023T1/sl unknown
- 2006-12-12 AU AU2006326548A patent/AU2006326548B2/en active Active
- 2006-12-12 CN CNA2006800527507A patent/CN101448826A/zh not_active Withdrawn
- 2006-12-12 ES ES06839328T patent/ES2373688T3/es active Active
- 2006-12-12 SI SI200632135A patent/SI2426129T1/sl unknown
- 2006-12-12 SI SI200632133A patent/SI2455382T1/sl unknown
- 2006-12-12 ES ES11152677.8T patent/ES2561507T3/es active Active
- 2006-12-12 JP JP2008545733A patent/JP5017278B2/ja active Active
- 2006-12-12 DK DK16197502.4T patent/DK3184526T3/en active
- 2006-12-12 RS RS20170081A patent/RS55634B1/sr unknown
- 2006-12-12 SI SI200632020A patent/SI2343299T1/sl unknown
- 2006-12-12 ES ES11152674.5T patent/ES2543903T3/es active Active
- 2006-12-12 RS RS20160052A patent/RS54683B1/sr unknown
- 2006-12-12 TW TW095146502A patent/TWI410407B/zh active
- 2006-12-12 EP EP20206996.9A patent/EP3838903B1/en active Active
- 2006-12-12 KR KR1020127024523A patent/KR101324737B1/ko active Active
- 2006-12-12 PT PT111527230T patent/PT2426129T/pt unknown
- 2006-12-12 DK DK11152708.1T patent/DK2348023T5/da active
- 2006-12-12 LT LTEP16197502.4T patent/LT3184526T/lt unknown
- 2006-12-12 PL PL11152708T patent/PL2348023T3/pl unknown
- 2006-12-12 EA EA200870048A patent/EA019504B1/ru active Protection Beyond IP Right Term
- 2006-12-12 CN CN201310058988.2A patent/CN103214483B/zh active Active
- 2006-12-12 PL PL11152730T patent/PL2455382T3/pl unknown
- 2006-12-12 TW TW105120803A patent/TWI630207B/zh active
- 2006-12-12 EP EP18191992.9A patent/EP3466953B1/en active Active
- 2006-12-12 MY MYPI2013002970A patent/MY162590A/en unknown
- 2006-12-12 PL PL16197502T patent/PL3184526T3/pl unknown
- 2006-12-12 PL PL11152677.8T patent/PL2343299T3/pl unknown
- 2006-12-12 HU HUE16197502A patent/HUE041382T2/hu unknown
- 2006-12-12 BR BRPI0619817A patent/BRPI0619817B8/pt active IP Right Grant
- 2006-12-12 LT LTEP11152714.9T patent/LT2474545T/lt unknown
- 2006-12-12 EP EP11152714.9A patent/EP2474545B1/en active Active
- 2006-12-12 UA UAA201115478A patent/UA116187C2/uk unknown
- 2006-12-12 SG SG2012014957A patent/SG179430A1/en unknown
- 2006-12-12 ES ES11152708.1T patent/ES2543904T3/es active Active
- 2006-12-12 EP EP11152708.1A patent/EP2348023B9/en active Active
- 2006-12-12 RS RS20170047A patent/RS55576B1/sr unknown
- 2006-12-12 HU HUE11152677A patent/HUE028588T2/hu unknown
- 2006-12-12 EP EP11152723.0A patent/EP2426129B1/en active Active
- 2006-12-12 ES ES20206996T patent/ES2970354T3/es active Active
- 2006-12-12 CN CN201310059187.8A patent/CN103214484B/zh active Active
- 2006-12-12 DK DK06839328.9T patent/DK1966202T3/da active
- 2006-12-12 NZ NZ569015A patent/NZ569015A/en unknown
- 2006-12-12 US US11/637,545 patent/US7598257B2/en active Active
- 2006-12-12 PT PT06839328T patent/PT1966202E/pt unknown
- 2006-12-12 PL PL06839328T patent/PL1966202T3/pl unknown
- 2006-12-12 DK DK11152677.8T patent/DK2343299T3/en active
- 2006-12-12 EP EP16197502.4A patent/EP3184526B1/en active Active
- 2006-12-12 PL PL11152723T patent/PL2426129T3/pl unknown
- 2006-12-12 HU HUE11152730A patent/HUE030418T2/en unknown
- 2006-12-12 PT PT16197502T patent/PT3184526T/pt unknown
- 2006-12-12 EP EP11152674.5A patent/EP2343298B9/en active Active
- 2006-12-12 PT PT111527149T patent/PT2474545T/pt unknown
- 2006-12-12 ES ES11152714.9T patent/ES2612489T3/es active Active
- 2006-12-12 MY MYPI20082099A patent/MY159449A/en unknown
- 2006-12-12 WO PCT/US2006/047369 patent/WO2007070514A1/en not_active Ceased
- 2006-12-12 SI SI200632137A patent/SI2474545T1/sl unknown
- 2006-12-12 TW TW107113620A patent/TWI664182B/zh active
- 2006-12-12 HU HUE11152714A patent/HUE032337T2/en unknown
- 2006-12-12 DK DK11152714.9T patent/DK2474545T3/en active
- 2006-12-12 SG SG10201506912RA patent/SG10201506912RA/en unknown
- 2006-12-12 DK DK11152723.0T patent/DK2426129T3/en active
- 2006-12-12 PT PT111526778T patent/PT2343299E/pt unknown
- 2006-12-12 AT AT06839328T patent/ATE525374T1/de active
- 2006-12-12 TW TW103136068A patent/TWI553008B/zh active
- 2006-12-12 ME MEP-2011-199A patent/ME01312B/me unknown
- 2006-12-12 SI SI200631209T patent/SI1966202T1/sl unknown
- 2006-12-12 ES ES16197502T patent/ES2700433T3/es active Active
- 2006-12-12 ES ES11152730.5T patent/ES2611588T3/es active Active
- 2006-12-12 ES ES11152723.0T patent/ES2612196T3/es active Active
- 2006-12-12 HU HUE11152708A patent/HUE025173T2/hu unknown
- 2006-12-12 EP EP11152730.5A patent/EP2455382B1/en active Active
- 2006-12-12 CN CN201310058991.4A patent/CN103254190B/zh active Active
- 2006-12-12 EP EP06839328A patent/EP1966202B1/en active Active
- 2006-12-12 KR KR1020117029741A patent/KR101218214B1/ko active Active
- 2006-12-12 TW TW101121442A patent/TWI468162B/zh active
- 2006-12-12 HR HR20110903T patent/HRP20110903T1/hr unknown
- 2006-12-12 KR KR1020127024525A patent/KR101391900B1/ko active Active
- 2006-12-12 SG SG10202003901UA patent/SG10202003901UA/en unknown
- 2006-12-12 DK DK11152730.5T patent/DK2455382T3/da active
- 2006-12-12 RS RS20170079A patent/RS55632B1/sr unknown
- 2006-12-12 TW TW103117669A patent/TW201434835A/zh unknown
- 2006-12-12 EP EP11152677.8A patent/EP2343299B9/en active Active
- 2006-12-12 LT LTEP11152723.0T patent/LT2426129T/lt unknown
- 2006-12-12 RS RS20150513A patent/RS54181B9/sr unknown
- 2006-12-12 UA UAA200809072A patent/UA98449C2/ru unknown
- 2006-12-12 HU HUE11152723A patent/HUE030235T2/en unknown
- 2006-12-12 SI SI200632294T patent/SI3184526T1/sl unknown
- 2006-12-12 EA EA201200132A patent/EA035795B1/ru active Protection Beyond IP Right Term
- 2006-12-12 MX MX2015003466A patent/MX346183B/es unknown
- 2006-12-12 RS RS20181405A patent/RS58113B1/sr unknown
- 2006-12-12 RS RS20110571A patent/RS52101B/sr unknown
- 2006-12-12 PL PL11152714T patent/PL2474545T3/pl unknown
- 2006-12-13 AR ARP060105499A patent/AR057995A1/es active IP Right Grant
-
2008
- 2008-06-05 IL IL192019A patent/IL192019A/en active IP Right Grant
- 2008-06-12 CR CR10065A patent/CR10065A/es unknown
- 2008-06-12 ZA ZA2008/05165A patent/ZA200805165B/en unknown
- 2008-06-12 US US12/138,082 patent/US8415362B2/en active Active
- 2008-06-13 EC EC2008008540A patent/ECSP088540A/es unknown
- 2008-07-11 KR KR1020087017011A patent/KR101216055B1/ko active Active
-
2009
- 2009-08-27 US US12/549,170 patent/US8541425B2/en active Active
-
2011
- 2011-03-30 US US13/076,220 patent/US8530485B2/en active Active
- 2011-03-30 US US13/076,176 patent/US8946245B2/en active Active
- 2011-09-05 JP JP2011192962A patent/JP5710430B2/ja active Active
- 2011-12-20 CY CY20111101270T patent/CY1112762T1/el unknown
-
2012
- 2012-03-08 EC ECSP12008540 patent/ECSP12008540A/es unknown
-
2013
- 2013-01-09 LT LTPA2013002C patent/LTPA2013002I1/lt unknown
- 2013-01-18 LU LU92137C patent/LU92137I2/fr unknown
- 2013-01-21 FR FR13C0007C patent/FR13C0007I2/fr active Active
- 2013-02-15 CY CY2013006C patent/CY2013006I2/el unknown
- 2013-02-19 BE BE2013C014C patent/BE2013C014I2/fr unknown
- 2013-09-06 US US14/020,505 patent/US9206187B2/en active Active
- 2013-09-20 US US14/033,039 patent/US8933086B2/en active Active
- 2013-10-03 CR CR20130506A patent/CR20130506A/es unknown
- 2013-12-17 JP JP2013260480A patent/JP5876026B2/ja active Active
-
2014
- 2014-04-08 IL IL231992A patent/IL231992A/en active IP Right Grant
- 2014-05-12 US US14/274,948 patent/US9079912B2/en active Active
-
2015
- 2015-05-13 US US14/711,576 patent/US20150238492A1/en not_active Abandoned
- 2015-07-06 JP JP2015135307A patent/JP6138865B2/ja active Active
- 2015-07-31 CY CY20151100673T patent/CY1116574T1/el unknown
- 2015-08-06 HR HRP20150837TT patent/HRP20150837T2/hr unknown
-
2016
- 2016-02-02 HR HRP20160112TT patent/HRP20160112T1/hr unknown
- 2016-06-03 US US15/173,057 patent/US9662335B2/en active Active
- 2016-08-10 US US15/233,652 patent/US9814722B2/en active Active
- 2016-11-13 IL IL248938A patent/IL248938A0/en unknown
- 2016-11-21 US US15/356,957 patent/US9974790B2/en active Active
-
2017
- 2017-01-19 HR HRP20170090TT patent/HRP20170090T1/hr unknown
- 2017-01-20 CY CY20171100089T patent/CY1118506T1/el unknown
- 2017-01-30 CY CY20171100130T patent/CY1118724T1/el unknown
- 2017-02-01 HR HRP20170162TT patent/HRP20170162T1/hr unknown
- 2017-02-07 HR HRP20170200TT patent/HRP20170200T1/hr unknown
- 2017-02-08 CY CY20171100171T patent/CY1118607T1/el unknown
- 2017-04-25 LT LTPA2017012C patent/LTPA2017012I1/lt unknown
- 2017-04-25 FR FR17C1013C patent/FR17C1013I2/fr active Active
- 2017-04-25 HU HUS1700017C patent/HUS1700017I1/hu unknown
- 2017-04-25 CY CY2017015C patent/CY2017015I2/el unknown
-
2018
- 2018-04-23 US US15/960,069 patent/US10398699B2/en active Active
- 2018-11-01 US US16/177,602 patent/US10639310B2/en active Active
- 2018-11-16 HR HRP20181912TT patent/HRP20181912T1/hr unknown
- 2018-12-27 CY CY20181101401T patent/CY1121202T1/el unknown
-
2020
- 2020-03-17 US US16/821,624 patent/US11331320B2/en active Active
-
2022
- 2022-03-08 US US17/689,510 patent/US11744832B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11331320B2 (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | |
| US20130137681A1 (en) | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | |
| AU2025200056B2 (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | |
| HK40051731A (en) | Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor | |
| HK1240224B (en) | Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor | |
| HK1124840B (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | |
| HK1173439A (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | |
| HK1240224A1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor |